Start of Trial Triggers €4.3M Payment to Biocompatibles
BioWorld International Correspondent
LONDON - Biocompatibles International plc moved onto the next stage of its collaboration with AstraZeneca plc, agreeing to a schedule for the Phase I and Phase II trials of the Type II diabetes drug CM3, and thus triggering a further €4.3 million (US$6.4 million) payment from the pharma company.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST